source
- Boehringer targets 2027 submission of obesity drug survodutide after positive cardiovascular trialBoehringer Ingelheim announced that its experimental obesity therapy survodutide is moving toward regulatory filing. The move follows the drug's successful phase 3 cardiovascular outcomes study, w…
- Immunocore reports early data showing 70% two-year survival with brenetafusp/Kimmtrak combo in uveal melanomaImmunocore presented early clinical data on its bispecific T-cell engager combination brenetafusp and Kimmtrak in patients with uveal melanoma. The analysis, based on a subset of patients, indicat…Endpoints · 3d agoPositive readoutPositive